JP2025063134A5 - - Google Patents
Info
- Publication number
- JP2025063134A5 JP2025063134A5 JP2025003271A JP2025003271A JP2025063134A5 JP 2025063134 A5 JP2025063134 A5 JP 2025063134A5 JP 2025003271 A JP2025003271 A JP 2025003271A JP 2025003271 A JP2025003271 A JP 2025003271A JP 2025063134 A5 JP2025063134 A5 JP 2025063134A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- ror
- antagonist antibody
- chemotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641035P | 2018-03-09 | 2018-03-09 | |
| US62/641,035 | 2018-03-09 | ||
| JP2020547097A JP2021517135A (ja) | 2018-03-09 | 2019-03-11 | 化学療法抵抗性がんの組合せ処置 |
| PCT/US2019/021694 WO2019173843A1 (en) | 2018-03-09 | 2019-03-11 | Combination treatment of chemoresistant cancers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547097A Division JP2021517135A (ja) | 2018-03-09 | 2019-03-11 | 化学療法抵抗性がんの組合せ処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025063134A JP2025063134A (ja) | 2025-04-15 |
| JP2025063134A5 true JP2025063134A5 (https=) | 2025-08-27 |
Family
ID=67846369
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547097A Pending JP2021517135A (ja) | 2018-03-09 | 2019-03-11 | 化学療法抵抗性がんの組合せ処置 |
| JP2025003271A Pending JP2025063134A (ja) | 2018-03-09 | 2025-01-09 | 化学療法抵抗性がんの組合せ処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547097A Pending JP2021517135A (ja) | 2018-03-09 | 2019-03-11 | 化学療法抵抗性がんの組合せ処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11883492B2 (https=) |
| EP (1) | EP3762428A4 (https=) |
| JP (2) | JP2021517135A (https=) |
| CN (1) | CN112262157A (https=) |
| AU (1) | AU2019231321B2 (https=) |
| WO (1) | WO2019173843A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121471361A (zh) | 2022-03-09 | 2026-02-06 | 杭州中美华东制药有限公司 | 一种靶向ror1的结合分子及其应用 |
| CN120865418B (zh) * | 2025-09-28 | 2025-12-30 | 成都微芯新域生物技术有限公司 | 抗ror1抗体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2361085T4 (en) * | 2008-11-22 | 2018-10-08 | Hoffmann La Roche | USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER |
| JP2013529203A (ja) * | 2010-05-14 | 2013-07-18 | ジェネンテック， インコーポレイテッド | 治療方法 |
| EP3604339B1 (en) * | 2011-01-14 | 2021-03-10 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| ES2702315T3 (es) | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| WO2016187220A2 (en) * | 2015-05-18 | 2016-11-24 | Five Prime Therapeutics, Inc. | Anti-ror1 antibodies |
| TWI767915B (zh) | 2016-06-27 | 2022-06-21 | 加州大學董事會 | Ror-1與btk拮抗劑的組合 |
-
2019
- 2019-03-11 JP JP2020547097A patent/JP2021517135A/ja active Pending
- 2019-03-11 CN CN201980031078.0A patent/CN112262157A/zh active Pending
- 2019-03-11 WO PCT/US2019/021694 patent/WO2019173843A1/en not_active Ceased
- 2019-03-11 US US16/979,469 patent/US11883492B2/en active Active
- 2019-03-11 EP EP19764748.0A patent/EP3762428A4/en active Pending
- 2019-03-11 AU AU2019231321A patent/AU2019231321B2/en active Active
-
2025
- 2025-01-09 JP JP2025003271A patent/JP2025063134A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025063134A5 (https=) | ||
| AU2018288060B2 (en) | IL-1beta binding antibodies for use in treating cancer | |
| JP2013520442A5 (https=) | ||
| JP2023507190A5 (https=) | ||
| JP2021515017A5 (https=) | ||
| JP2018531278A6 (ja) | 癌のための併用療法 | |
| JP2018531278A (ja) | 癌のための併用療法 | |
| JP2022541591A5 (https=) | ||
| JP2022531408A5 (https=) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2010534685A (ja) | チロシンキナーゼ阻害剤およびインテグリンα５β１（ＣＤ４９Ｅ）に対する抗体を含む薬学的な組み合わせ | |
| JP2024069230A5 (https=) | ||
| CN114340679A (zh) | 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物 | |
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| WO2020236667A1 (en) | Methods of treating cancer | |
| JP2021517135A5 (https=) | ||
| TW202130349A (zh) | Ｐｄ－１抗體聯合紫杉類化合物在製備治療三陰性乳腺癌的藥物中的用途 | |
| CN121311246A (zh) | 癌症治疗与预防的组合疗法 | |
| CN119055767A (zh) | 包含抗her2双特异性抗体的联合治疗药物及其用途 | |
| CN117427186A (zh) | 抗her2抗体药物偶联物联合抗pd-l1抗体在制备治疗肺癌的药物中的用途 | |
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| US20220119507A1 (en) | Medicinal composition containing monoclonal antibody or antibody fab fragment thereof, and use thereof | |
| WO2016062280A1 (zh) | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用于促进血管新生以改善组织缺血及糖尿病血管病变的用途 |